Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 318 for:    IBRUTINIB

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02943473
Recruitment Status : Recruiting
First Posted : October 24, 2016
Last Update Posted : March 22, 2019
Sponsor:
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Ajai Chari, Icahn School of Medicine at Mount Sinai

Brief Summary:

The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma. The researchers conducting this trial) have reason to believe that ibrutinib can delay the development of multiple myeloma, thus giving people who currently have smoldering myeloma a longer period of time when they feel healthy and well.

Smoldering myeloma is an abnormal condition that is considered to be an early phase of the disease multiple myeloma. In this disorder, there is an abnormal growth of plasma cells, which is a type of blood cell found in the bone marrow. This growth is not as severe in people with smoldering myeloma as it is in multiple myeloma, so people with smoldering myeloma do not have any symptoms and tend to feel well. However, they have a higher risk of developing multiple myeloma than people in the general population.

Some people with smoldering myeloma are at an especially high risk of developing myeloma - 50% of these people will develop multiple myeloma 2 years after they are diagnosed with smoldering myeloma. The investigators identify these people by looking at the amount of myeloma in the bone marrow (called "bone marrow plasma cell percentage") and the amount of myeloma protein (called "serum protein electrophoresis" and "serum free light chain assay") in the blood. To be considered high risk, individuals must have highly abnormal levels for these tests.

Based upon current guidelines, people with smoldering myeloma do not require any treatment. However, known is that many of these people will develop multiple myeloma in the near future. Currently there have been no proven and effective way of preventing these people from developing multiple myeloma, which remains an incurable disease.


Condition or disease Intervention/treatment Phase
High Risk Smoldering Multiple Myeloma Drug: Ibrutinib Phase 2

Detailed Description:

This is a phase 2, open-label, single center, prospective pilot study designed to assess the efficacy of ibrutinib in subjects with high risk smoldering multiple myeloma.

All enrolled subjects will be treated with ibrutinib 560 mg (4 capsules, each containing 140 mg) taken PO daily for 12 cycles (28 days each). If a subject demonstrates benefit from ibrutinib, therapy may be extended beyond 12 cycles to a maximum of 2 years. Subjects who progress and meet criteria for symptomatic multiple myeloma will be withdrawn from study.

An initial cohort of 15 subjects will be accrued. If 4 or more patients progress to symptomatic myeloma in one year, then the study will be reviewed with the FDA to determine whether to employ a higher dose of ibrutinib, or to stop for futility. Otherwise, 21 additional patients will be accrued for a total sample size of 36.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma
Study Start Date : November 2016
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: Ibrutinib
Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
Drug: Ibrutinib
Ibrutinib is a type of drug called a "kinase inhibitor." Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.
Other Name: IMBRUVICA




Primary Outcome Measures :
  1. Number of patients without symptomatic myeloma [ Time Frame: up to 1 year ]
    Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.


Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: up to 1 year ]
    Overall response rate, defined as partial response or better per IMWG criteria. (IMWG response criteria are - Complete Response, Very good partial response, partial response, Minimal response, stable disease, and progressive disease)

  2. Bone Density Changes [ Time Frame: baseline and one year ]
    Changes in bone density, particularly in patients with osteopenia (defined as T-score on bone densitometry testing (DEXA) of -1 to -2.5).

  3. PET-MRI Changes [ Time Frame: baseline and one year ]
    Changes in PET-MRI, particularly in patients with osteopenia

  4. Change in Serum interleukin-6 (IL-6) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  5. Change in Serum stromal cell-derived factor-1 (SDF-1) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  6. Change in Serum receptor activator of nuclear-factor kappa B ligand (RANKL) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  7. Change in Serum macrophage inflammatory protein-1α (MIP-1α) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  8. Change in Serum Dickkopf-1 (DKK-1) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  9. Change in Serum C-terminal telopeptide (CTX) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes

  10. Change in Urine N-terminal telopeptide (NTx) [ Time Frame: baseline and up to one year ]
    Bone Related Biomarker Changes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria Disease Related

  1. High risk SMM, defined as follows by Mayo Clinic criteria:

    1. Bone marrow plasma cells between 10% and 60%
    2. Serum M-protein ≥ 3 g/dL [except IgA ≥ 2 g/dL] or urine M-protein > 500 mg per 24 hours
    3. Serum free light chain ratio < 0.126 or > 8; an involved to uninvolved ratio of ≥ 100 is permitted
    4. Measurable disease, defined as: M-protein ≥ 1 g/dL OR Bence-Jones protein (BJP) > 200 mg/24 hr OR involved free light chain > 100 mg/dL
  2. Diagnosed with SMM within the last 4 years

Laboratory

  1. Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoetin which require at least 14 days prior to screening defined as:

    • Absolute neutrophil count > 750 cells/mm3 (1.0 x 109/L).
    • Platelet count > 75,000 cells/mm3 (75 x 109/L).
  2. Adequate hepatic and renal function defined as:

    • Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN).
    • Estimated creatinine clearance ≥ 30 ml/min (Cockcroft-Gault)
    • Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, in which case the total bilirubin should be < 3 x ULN)
  3. PT/INR < 1.5 x ULN and PTT (aPTT) < 1.5 x ULN

    Demographic

  4. Men and women ≥ 18 years of age
  5. Eastern Cooperative Oncology Group (ECOG) performance status of < 2

Exclusion Criteria Disease-Related

  1. No end organ damage attributable to a plasma cell disorder, defined as having ANY of the following:

    1. Hypercalcemia: Serum calcium > 1 mg/dL above the upper limit of normal or > 11 mg/dL
    2. Renal insufficiency: Serum creatinine > 2 mg/dL or creatinine clearance < 30 mL per min
    3. Anemia: Hemoglobin value > 2 g/dL below the upper limit of normal or a hemoglobin value < 10 g/dL
    4. Bone lesions: One or more lytic lesions on skeletal radiography, CT, MRI, PET-CT, or PET-MRI
  2. Bone marrow plasma cells < 10% or > 60%
  3. Has received prior anti-myeloma therapy of any type
  4. Has received prior bisphosphonate therapy
  5. Has received an investigational drug, investigational vaccine, or has used an investigational medical device within 4 weeks or 4 half-lives, whichever is longer, before Cycle 1, Day 1 of study therapy
  6. Osteoporosis, defined as having a T-score on DEXA of ≤ -2.5

Concurrent Conditions

  1. History of other malignancies, except:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
  2. Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc). Any use of corticosteroids EITHER for > 14 days OR at dosages > 20 mg/day of prednisone or equivalent is prohibited.
  3. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
  4. Recent infection requiring systemic treatment that was completed ≤ 14 days before the first dose of study drug
  5. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
  6. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  7. Known HIV, HCV or HBV infection. Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  8. Any uncontrolled active systemic infection
  9. Major surgery within 4 weeks of first dose of study drug
  10. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators' opinion, could compromise the subject's safety or put the study outcomes at undue risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02943473


Contacts
Layout table for location contacts
Contact: Lisa La, MS 212-241-7873 lisa.la@mssm.edu
Contact: Ajai Chari, MD 212-241-7873 ajai.chari@mountsinai.org

Locations
Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Ajai Chari, MD    212-241-7873    ajai.chari@mountsinai.org   
Principal Investigator: Ajai Chari, MD         
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Pharmacyclics LLC.
Investigators
Layout table for investigator information
Principal Investigator: Ajai Chari, MD Icahn School of Medicine at Mount Sinai

Layout table for additonal information
Responsible Party: Ajai Chari, Associate Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT02943473     History of Changes
Other Study ID Numbers: GCO 16-1867
First Posted: October 24, 2016    Key Record Dates
Last Update Posted: March 22, 2019
Last Verified: March 2019
Keywords provided by Ajai Chari, Icahn School of Medicine at Mount Sinai:
Smoldering multiple myeloma
myeloma
smoldering
ibrutinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Smoldering Multiple Myeloma
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Hypergammaglobulinemia